Biological
Prizloncabtagene autoleucel clinical trials
- studies test it
- 8
- open now
- 2
- in phase 3
- 0
- first study started
- 2019
Keep track of what changes. Save the prizloncabtagene autoleucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 6
First Affiliated Hospital of Zhejiang University (1) · Peking University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Peking Union Medical College Hospital (1) · Shanghai Tongji Hospital, Tongji University School of Medicine (1) · AbelZeta Inc. (1) · Shanghai AbelZeta Ltd. (1) · Canyon City Eyecare (1)
Studies
Open first, then newest update. How each study uses prizloncabtagene autoleucel is read from its arms, and is right about nine times in ten.
Testing it · 8
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyNot yet recruitingPhase 2AbelZeta Inc.NCT07875413Written as Prizloncabtagene Autoleucel
- A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell LymphomaRecruitingPhase 1/2Shanghai AbelZeta Ltd.NCT05800977Written as Prizloncabtagene autoleucel
- A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's LymphomaCompletedPhase 1Peking UniversityNCT05149391Written as CD19/CD20-directed Chimeric Antigen Receptor T Cells
- A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedPhase 1Tianjin Medical University Cancer Institute and HospitalNCT04696432Written as Prizloncabtagene autoleucel
- A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedPhase 1Peking Union Medical College HospitalNCT04655677Written as Prizloncabtagene Autoleucel
- A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL SubjectsCompletedPhase 1Shanghai Tongji Hospital, Tongji University School of MedicineNCT04317885Written as Prizloncabtagene Autoleucel
- A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's LymphomaActive, not recruitingPhase 1First Affiliated Hospital of Zhejiang UniversityNCT04693676Written as Prizloncabtagene Autoleucel
- A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or HyperopiaStatus unknownPhase 1/2Canyon City EyecareNCT04883996Written as 1% EXP039
Codes
What other systems call prizloncabtagene autoleucel · ClinicalTrials.gg INT014592
- UNII (FDA) 35X9XB2HBGPRIZLONCABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C178452Prizloncabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 35X9XB2HBG | PRIZLONCABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C178452 | Prizloncabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.